Combination of nivolumab and ipilimumab in the treatment of disseminated renal cell carcinoma. Realities and prospects
https://doi.org/10.17650/1726-9776-2020-16-3-38-52
Abstract
The use of immunotherapeutic drugs as monotherapy and in various combinations for metastatic renal cell carcinoma has revolutionized the treatment of this disease. Thanks to the breakthrough studies carried out, the standard in the first line of therapy for metastatic renal cell carcinoma is now a combination of checkpoint inhibitors, as well as an immuno-oncological agent with a tyrosine kinase inhibitor.
This article presents updated data from the CheckMate 214 study with a minimum follow-up of 42 months. A review of studies on the efficacy of nivolumab in patients with renal cell carcinoma in the first line of therapy with the possibility of adding ipilimumab in case of progression of the disease on the background of monotherapy is carried out, as well as data on the use of a combination of nivolumab and ipilimumab in the second line of treatment.
Monotherapy with nivolumab has a certain effectiveness in a specific category of patients, for example, with potential intolerance to ipilim-umab or first-line tyrosine kinase inhibitors, as well as in patients with a favorable prognosis.
The combination of drugs nivolumab + ipilimumab is a highly effective treatment option in the first line of therapy with the potential for a sustained response in patients with RCC with an poor and intermediate risk, and in the second and subsequent lines requires further study.
About the Authors
B. Ya. Alekseev
National Medical Research Radiological Center, Ministry of Health of Russia; Department of Oncology, Medical Institute of Continuing Education, Moscow State University of Food Production
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284; 11 Volokolamskoe Shosse, Moscow 125080.
Competing Interests: The authors declare no conflict of interest.
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284; 11 Volokolamskoe Shosse, Moscow 125080.
Competing Interests: The authors declare no conflict of interest.
I. M. Shevchuk
National Medical Research Radiological Center, Ministry of Health of Russia; Department of Oncology, Medical Institute of Continuing Education, Moscow State University of Food Production
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284; 11 Volokolamskoe Shosse, Moscow 125080.
Competing Interests: The authors declare no conflict of interest.
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284; 11 Volokolamskoe Shosse, Moscow 125080.
Competing Interests: The authors declare no conflict of interest.
References
1. Rini B.I., Battle D., Figlin R.A. et al. The Society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer 2019;7(1):354. DOI: 10.1186/s40425-019-0813-8.
2. Motzer R.J., Tannir N.M., McDermott D.F. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378:1277-90. DOI: 10.1056/NEJMoa1712126.
3. Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:1116-27. DOI: 10.1056/NEJMoa1816714.
4. Motzer R.J., Rini B.I., McDermott D.F. et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019;20:1370-85. DOI: 10.1016/S1470-2045(19)30413-9.
5. Motzer R.J., McDermott D.F., Escudier B. et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer 2020;8(2):e000891. DOI: 10.1136/jitc-2020-000891.
6. Tannir N.M., McDermott D.F., Escudier B. et al. Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). ASCO GU 2020. NCT02231749.
7. Masuda K., Shoji H., Nagashima K. et al. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer 2019;19(1):974. DOI: 10.1186/s12885-019-6150-y.
8. Haratani K., Hayashi H., Chiba Y. et al. Association of immune-related adverse events with nivolumab efficacy in nonsmall-cell lung cancer. JAMA Oncol 2018;4(3):374-8. DOI: 10.1001/jamaoncol.2017.2925.
9. Toi Y., Sugawara S., Kawashima Y. et al. Association of immunerelated adverse events with clinical benefit in patients with advanced non-smallcell lung cancer treated with nivolumab. Oncologist 2018;23(11):1358-65. DOI: 10.1634/theoncologist.2017-0384.
10. Atkins M., Jegede O., Haas N. et al. Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naive patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260). J Clin Oncol 2020;38:abstract 5006.
11. McKay R., Xie W., McGregor B. et al. Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE). J Clin Oncol 2020;38:abstract 5005.
12. Choueiri T.K., Kluger H.M., George S. et al. FRACTION-RCC: innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC). J Clin Oncol 2020;38:abstract 5007.
Review
For citations:
Alekseev B.Ya., Shevchuk I.M. Combination of nivolumab and ipilimumab in the treatment of disseminated renal cell carcinoma. Realities and prospects. Cancer Urology. 2020;16(3):38-52. (In Russ.) https://doi.org/10.17650/1726-9776-2020-16-3-38-52
Views:
2720
Email this article 